Schedule 13D ownership disclosure

MATINAS BIOPHARMA HLDGS INC

Common Stock, $0.0001 par value per share · CUSIP: 576810303

Event date: 2025-04-08

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Pembroke & Partners LLCReported CIK 0002056785

    Shares: 16,894,212 · Class: 9.99%

  • Robert J. EideReported CIK 0001181955

    Shares: 16,895,712 · Class: 9.99%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001477932-25-002577
Form type
SCHEDULE 13D/A
Filer
Matinas BioPharma Holdings, Inc.
CIK
CIK 1582554
Filed
Apr 10, 2025
Reporting period
Apr 08, 2025
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub